AssetMark Inc’s Ascendis Pharma A/S ASND Stock Holding History

AssetMark Inc’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.78M	Buy	16,611 +3,116	+23%	+$789K	0.01%	801
2026 Q2	$3.6M	Buy	13,495 +3,860	+40%	+$902K	0.01%	823
2026 Q1	$2.2M	Buy	9,635 +1,056	+12%	+$237K	﹤0.01%	865
2025 Q4	$1.83M	Buy	8,579 +2,787	+48%	+$576K	﹤0.01%	875
2025 Q3	$1.15M	Buy	5,792 +3,414	+144%	+$637K	﹤0.01%	945
2025 Q2	$410K	Buy	2,378 +2,309	+3,346%	+$376K	﹤0.01%	1083
2025 Q1	$10.8K	Sell	69 -2,873	-98%	-$410K	﹤0.01%	1839
2024 Q4	$405K	Buy	2,942 +728	+33%	+$95.7K	﹤0.01%	988
2024 Q3	$331K	Buy	+2,214	New	+$299K	﹤0.01%	944

Other funds holding ASND

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Braun Stacey Associates New York $3.48B AUM 48.73% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Matisse Capital Portland, Oregon $256M AUM 15.28% 1-Year Est. Return

Henry James International Management New York $330M AUM 35.5% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return

AssetMark Inc's ASND Position: Q3 2026 in Review

AssetMark Inc increased its Ascendis Pharma A/S (ASND) stake by 23% in Q3 2026, buying an estimated $789K and bringing the position to 16,611 shares worth $3.78M. The position accounts for 0.01% of the portfolio, ranked #801.

AssetMark Inc first reported a position in ASND in Q3 2024 and has held it in 9 quarters since. 98 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

AssetMark Inc held 16,611 shares of Ascendis Pharma A/S worth $3.78M as of Q3 2026.
AssetMark Inc bought 3,116 Ascendis Pharma A/S shares in Q3 2026, an estimated $789K.
Ascendis Pharma A/S made up 0.01% of AssetMark Inc's portfolio in Q3 2026, its #801 holding.
AssetMark Inc first reported a position in Ascendis Pharma A/S in Q3 2024 and has held it in 9 quarters since.
98 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.